Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-02-12

Clinical Trial Update: JAK Inhibitor Treatment in AGS [Phase 2]

View source ↗

Summary

Phase 2 trial of a JAK inhibitor in Aicardi-Goutières syndrome has completed, with results posted on 2025-02-12.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • JAK inhibitor

Snippet

Sponsor: Adeline Vanderver, MD | Conditions: Aicardi Goutieres Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2025-02-12